Antipsychotic-induced weight gain and therapeutic response: A differential association

Pál Czobor, Jan Volavka, Brian Sheitman, Jean Pierre Lindenmayer, Leslie Citrome, Joseph McEvoy, Thomas B. Cooper, Miranda Chakos, Jeffrey A. Lieberman

Research output: Contribution to journalArticlepeer-review

175 Scopus citations


This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients enrolled in a double-blind experiment with a duration of 14 weeks comparing the therapeutic efficacy of haloperidol (n = 36), clozapine (n = 38), olanzapine (n = 38), and risperidone (n = 39). Absolute and relative (%) gain in body weight and body mass index (BMI) was determined for the entire duration of the double-blind treatment period; therapeutic response was assessed by the total score and the individual subscales of the Positive and Negative Symptom Scale. Compared with the pretreatment baseline, results indicated that for olanzapine and clozapine, therapeutic response was closely related to an absolute and relative gain in weight and to a gain in BMI. No association between weight gain and therapeutic response was found for risperidone and haloperidol. These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain.

Original languageEnglish (US)
Pages (from-to)244-251
Number of pages8
JournalJournal of Clinical Psychopharmacology
Issue number3
StatePublished - 2002
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Antipsychotic-induced weight gain and therapeutic response: A differential association'. Together they form a unique fingerprint.

Cite this